메타돈 및 메타돈인터미디에이트;3-헵타논,6-(다이메틸아미노)-4,4-다이페닐-

메타돈 및 메타돈인터미디에이트;3-헵타논,6-(다이메틸아미노)-4,4-다이페닐-
메타돈 및 메타돈인터미디에이트;3-헵타논,6-(다이메틸아미노)-4,4-다이페닐- 구조식 이미지
카스 번호:
76-99-3
한글명:
메타돈 및 메타돈인터미디에이트;3-헵타논,6-(다이메틸아미노)-4,4-다이페닐-
동의어(한글):
메타돈및메타돈인터미디에이트;3-헵타논,6-(다이메틸아미노)-4,4-다이페닐-
상품명:
(+/-)-METHADONE
동의어(영문):
k174;Adanon;Amidone;Mecodin;Eptadone;Diaminon;Dolophin;Heptanon;Ketalgin;Methadon
CBNumber:
CB9707025
분자식:
C21H27NO
포뮬러 무게:
309.45
MOL 파일:
76-99-3.mol

메타돈 및 메타돈인터미디에이트;3-헵타논,6-(다이메틸아미노)-4,4-다이페닐- 속성

녹는점
78°
끓는 점
449.71°C (rough estimate)
밀도
1.0350 (rough estimate)
굴절률
1.5614 (estimate)
인화점
9℃
저장 조건
−20°C
산도 계수 (pKa)
pKa 8.25 (Uncertain)
EPA
3-Heptanone, 6-(dimethylamino)-4,4-diphenyl- (76-99-3)
안전
  • 위험 및 안전 성명
  • 위험 및 사전주의 사항 (GHS)
위험품 표기 F,T
위험 카페고리 넘버 11-23/24/25-39/23/24/25
안전지침서 7-16-36/37-45
유엔번호(UN No.) UN1230 - class 3 - PG 2 - Methanol, solution
WGK 독일 1
유해 물질 데이터 76-99-3(Hazardous Substances Data)
독성 LD50 oral in rat: 86mg/kg
그림문자(GHS): GHS hazard pictogramsGHS hazard pictogramsGHS hazard pictograms
신호 어: Danger
유해·위험 문구:
암호 유해·위험 문구 위험 등급 범주 신호 어 그림 문자 P- 코드
H225 고인화성 액체 및 증기 인화성 액체 구분 2 위험 GHS hazard pictograms P210,P233, P240, P241, P242, P243,P280, P303+ P361+P353, P370+P378,P403+P235, P501
H370 장기(또는, 영향을 받은 알려진 모든 장기를 명시)에 손상을 일으킴(노출되어도 특정 표적장기 독성을 일으키지 않는다는 결정적인 노출경로가 있다면 노출경로를 기재) 특정 표적장기 독성 - 1회 노출 구분 1 위험 GHS hazard pictograms P260, P264, P270, P307+P311, P321,P405, P501
예방조치문구:
P210 열·스파크·화염·고열로부터 멀리하시오 - 금연 하시오.
P260 분진·흄·가스·미스트·증기·...·스프레이를 흡입하지 마시오.
P280 보호장갑/보호의/보안경/안면보호구를 착용하시오.
P301+P310 삼켰다면 즉시 의료기관(의사)의 진찰을 받으시오.
P311 의료기관(의사)의 진찰을 받으시오.

메타돈 및 메타돈인터미디에이트;3-헵타논,6-(다이메틸아미노)-4,4-다이페닐- C화학적 특성, 용도, 생산

용도

Analgesic (narcotic).

정의

ChEBI: A ketone that is heptan-3-one substituted by a dimethylamino group at position 6 and two phenyl groups at position 4.

Biological Functions

Methadone (Dolophine) has an analgesic profile and potency similar to that of morphine but a longer duration of action and better oral bioavailability.The kinetic properties of methadone and its derivative, LAAM, have been shown to be useful in the treatment of opioid addiction. Methadone is a useful analgesic drug for the treatment of moderate to severe pain. Unlike morphine, it is generally not used epidurally because of its long duration of action. It is also rarely or never used in PCA systems or in pregnant women during labor. The side effects and signs of overdose following methadone administration are similar to those observed with morphine. Overdose is treated with naloxone. Clearance of methadone is via the urine and bile as the cyclic Ndemethylated drug. The ability to N-demethylate the drug decreases in elderly patients, prolonging the action of methadone. In such patients, dosing intervals should be longer than in younger patients. In addition, the pH of the urine has a major effect on clearance of the drug. Alkalinization of the urine or renal insufficiency decreases excretion of the drug.
Drug interactions and precautions for the use of methadone are similar to those of morphine. In addition, rifampicin and hydantoins markedly increase the metabolism of methadone and can precipitate withdrawal from methadone. Conversely, the tricyclic antidepressants and certain benzodiazepines can inhibit metabolism of methadone, thereby increasing accumulation of the drug, prolonging its half-life, and intensifying its side effects. Continuous dosing with methadone may lead to drug accumulation and to an increased incidence of side effects; methadone is generally not used for PCA. In pregnant heroin-addicted women, substitution of methadone for heroin has been shown to be associated with fewer low-birth-weight newborns and fewer learning and cognition problems later in the life of the child.

일반 설명

Methadone (Dolophine) is a synthetic opioid approved for analgesic therapy and for the maintenance and treatment of opioid addiction. Methadone is marketed as the racemate, although the opioid activity resides in the R-enantiomer (7–50 times more potent than the S-enantiomer). Methadone may only be dispensed for the treatment of opioid addiction by a program certified by the Federal Substance Abuse and Mental Health Services Administration.
Methadone is a μ-receptor agonist with complex and highly variable pharmacokinetic parameters. The major metabolic pathway of methadone metabolism is via Ndemethylation to an unstable product that spontaneously cyclizes to form the inactive 2-ethylidene-1,5-dimethyl-3,3- diphenylpyrrolidine (EDDP).

Pharmacology

Methadone is a diphenylpropylamine. It has very good oral bioavailability (~85%) with an oral to parenteral ratio of 1:2. Its plasma half-life can be highly variable (3–50h, average 24h) but its duration of action is relatively short. With repeated dosing, problems with accumulation can occur because of this discrepancy between half-life and analgesic effect. Careful monitoring is therefore required when converting patients to long-term methadone. A lso, there is incomplete cross-tolerance with morphine. The racemic mixture in common use has agonist actions at the MOP receptor (mainly the laevo isomer) as well as antagonist activity at the NMDA receptor dextro isomer). Given the importance of this receptor in central sensitisation in a variety of pain states, there may be cases where methadone offers particular advantages over and above other opioids (e.g. neuropathic pain). Plasma concentrations of methadone can be reduced by carbamazepine, and its metabolism is accelerated by phenytoin.

Safety Profile

Poison by ingestion, intraperitoneal, intravenous, subcutaneous, and intraduodenal routes. Human systemic effects: coma, nausea or vomiting, respiratory changes, respiratory depression, somnolence. An experimental teratogen. Experimental reproductive effects. Caution: Abuse leads to habituation or addiction. When heated to decomposition it emits toxic fumes of NOx. See also METHADONE HYDROCHLORIDE.

메타돈 및 메타돈인터미디에이트;3-헵타논,6-(다이메틸아미노)-4,4-다이페닐- 준비 용품 및 원자재

원자재

준비 용품


메타돈 및 메타돈인터미디에이트;3-헵타논,6-(다이메틸아미노)-4,4-다이페닐- 관련 검색:

Copyright 2019 © ChemicalBook. All rights reserved